POMEGRANATE IN CARDIOVASCULAR DISEASES
Due to its rich chemical composition, pomegranate has been used since ancient times as a therapeutic agent for diseases of the cardiovascular system. Hippocrates, Avicenna and others wrote that pomegranate strengthens the stomach, is useful for water ascites, liver weakness, jaundice, spleen diseases, palpitations, and chest pain. The nature of acidic pomegranate is cold in the II degree and dry. If you eat it strongly, it will calm the fever, burning of the stomach and liver, calm the fever and blood pressure, bile, drive urine, prevent harmful fumes from rising to the brain, treat withdrawal, vomiting, heartbeat. All parts of the grenade help from interruptions in the heart. Modern scientific studies have shown that pomegranate juice has a hypotensive effect, inhibits angiotensin converting enzyme in patients with diseases of the cardiovascular system. Pomegranate juice is found to inhibit platelet aggregation and has antithrombotic properties. Pomegranate juice reduces low-density lipoprotein cholesterol concentration by 39% and increases high-density lipoprotein cholesterol concentration by 27%, resulting in a 12-18% reduction in cardiovascular disease risk. Pomegranate, its components (e.g. tannins, flavonoids, phytoestrogens, anthocyanins, alkaloids, etc.) have beneficial effects on the cardiovascular system, improving parameters such as oxidative stress and enzymatic antioxidant system, reducing the formation of reactive oxygen species and acting in an anti-inflammatory manner. Pomegranate seed oil has a protective effect against oxidative stress-induced damage in cardiomyocytes. Pomegranate juice causes a significant reduction in the intensity, occurrence, and duration of angina in patients with unstable angina, significantly lower serum troponin and malondialdehyde levels. Calcitriol extract and/or pomegranate peel had cardioprotective effects in pre-gestational diabetes due to antioxidant and anti-inflammatory properties and may be a promising treatment that directly targets secondary myocardial complications of diabetes in females and their offspring.